We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The high cost of AstraZeneca’s ovarian cancer treatment Lynparza doesn’t match the uncertainty of its survival benefits, the UK’s healthcare cost agency says. Read More
Upsher-Smith’s Qudexy XR is now available as a first-line monotherapy for children ages two and older who have partial-onset or tonic-clonic seizures. Read More
UCB’s Cimzia may soon be added to the list of arthritis drugs provided under England and Wales’ National Health Service, following a final draft recommendation by the UK’s healthcare cost watchdog. Read More
The FDA is clarifying its definition of “established conditions” to ensure drugmakers properly report postapproval chemistry, manufacturing and control changes in NDAs, ANDAs and BLAs. Read More
FDA approval of Pfizer subsidiary Wyeth’s Rapamune for lymphangioleiomyomatosis may be the light at the end of the tunnel for sufferers of the extremely rare lung disease. Read More